A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Epsi- Gam in Healthy, Cat-, Dust Mite-, or Bermuda Grass-Allergic Subjects

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Epsi- Gam in Healthy, Cat-, Dust Mite-, or Bermuda Grass-Allergic Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Epsi Gam (Primary)
  • Indications Hypersensitivity
  • Focus Adverse reactions
  • Sponsors Tunitas Therapeutics
  • Most Recent Events

    • 15 Jun 2016 Status changed from active, no longer recruiting to discontinued.
    • 17 May 2016 According to Tunitas Therapeutics media release, the company expects to have top-line results later this year and expand testing to the United States in 2017.
    • 06 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top